Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
NCT: NCT05168787 ·
Status: COMPLETED ·
Phase: N/A
· Sponsor: Methodist Health System
· Started: 2020-08-13
· Est. Completion: 2025-07-08
Official Summary
There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general. However, the mechanism of action of sacubitril specifically targets the activity of BNP. Therefore, there is the potential that the mechanism of action of sacubitril/valsartan may be less effective in AAs.
Study Design
- Study Type: OBSERVATIONAL
- Enrollment: 6,558 participants
Interventions
- DRUG: sacubitril/valsartan — Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.
Primary Outcomes
- Composite CV mortality or HF hospitalization (April 2017 to August 2020)
Secondary Outcomes
- CV mortality (April 2017 to August 2020)
- HF hospitalization (April 2017 to August 2020)
- All-cause mortality (April 2017 to August 2020)
- New atrial fibrillation (April 2017 to August 2020)
- Renal function decline (April 2017 to August 2020)
Trial Locations
- Methodist Dallas Medical Center Pharmacy, Dallas, Texas, United States
More Heart Failure Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.